Dinaciclib - CAS# 779353-01-4 Catalog No.:M10712-10 Small Molecule Inhibition of the

Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates

BRD0539 is stable in human plasma and reversibly inhibits SpCas9

is a potent and selective Rho kinase inhibitor

InChiKey: VJYKVCURWJGLPG-IQZGDKDPSA-N

Chronic oral administration of ZLN005 at 15 mg/kg per day to diabetic db/db mice increased PGC-1α and downstream gene transcription in skeletal muscle

Dinaciclib - CAS# 779353-01-4 Catalog No.:M10712-10 Small Molecule Inhibition of theDinaciclib, also known as SCH727965, is a potent CDK inhibitor with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9 activity in vitro with IC(50) values of 1, 1, 3, and 4 nmol L, respectively. Compared with flavopiridol, Dinaciclib exhibits superior activity with an improved therapeutic index. Dinaciclib induced regression of established solid tumors in a range of mouse models